AGC Biologics & Novelty Nobility Partner for Cell Line Development
Headquartered in Seattle, AGC Biologics has entered a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea.
As part of the partnership, AGC Biologics will develop the cell line and create a master cell bank (MCB) for Novelty Nobility’s bispecific antibody candidate at its Copenhagen facility. Novelty Nobility will leverage AGC Biologics’ expertise, proprietary CHEF1 expression technology, and additional process development.